D-环戊基甘氨酸 | 2521-86-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-环戊基甘氨酸
• 英文名称: D-cyclopentylglycine
• 英文别名: (2R)-2-azaniumyl-2-cyclopentylacetate
• CAS: 2521-86-0
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: XBPKRVHTESHFAA-ZCFIWIBFSA-N

物化性质

• 沸点：
  276.6±23.0 °C(Predicted)
• 密度：
  1.167±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: D-Cyclopentylglycine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: D-Cyclopentylglycine
CAS number: 2521-86-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H13NO2
Molecular weight: 143.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

D-环戊基甘氨酸是一种氨基酸衍生物，用作能量补充剂。

反应信息

• 作为反应物：
  描述：

  D-环戊基甘氨酸 在 碳酸氢钠 、 1-丙基磷酸酐 、 三乙胺 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 tert-butyl (R)-(2-(bicyclo[1.1.1]pentan-1-ylamino)-1-cyclopentyl-2-oxoethyl)carbamate
  参考文献：
  名称：

  3-((1,1-DIOXIDO-2,3,4,5-TETRAHYDROBENZO[F][1,2,5]THIADIAZEPIN-8-YL)OXY)-2-FLUOROACRYLIC ACID DERIVATIVES AS SODIUM TAUROCHOLATE CO-TRANSPORTING POLYPEPTIDE (NTCP) INHIBITORS FOR THE TREATMENT OF CHOLESTASIS

  摘要：

  Described herein are compounds of formula (A) and pharmaceutically acceptable forms thereof that are potent inhibitors of the sodium taurocholate co-transporting polypeptide (NTCP), pharmaceutical compositions comprising compounds of formula (A) and pharmaceutically acceptable salts thereof, as well as the compounds of formula (A) for use in methods of medical treatment of e.g. e.g. cholestasis, hepatitis, liver cirrhosis, liver failure and hepatocellular carcinoma. Preferred compounds are e.g. 3-((l,l-dioxido-2,3,4,5- tetrahydrobenzo[f][l,2,5]thiadiazepin-8-yl)oxy)-2-fluoroacrylic acid derivatives.

  公开号：

  WO2024163962A1
• 作为产物：
  描述：

  2-环戊烯-1-基(三甲基)硅烷 在 palladium on activated charcoal 三氟化硼乙醚 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， -78.0~25.0 ℃ 、275.79 kPa 条件下， 反应 20.25h， 生成 D-环戊基甘氨酸
  参考文献：
  名称：

  Synthesis of racemic .alpha.-amino carboxamides via Lewis acid-mediated reactions of .alpha.-methoxyglycinamide derivatives with allylsilanes: enzymic resolution to optically active .alpha.-amino acids

  摘要：

  A short and expedient synthetic route to optically active, saturated and gamma,delta-unsaturated alpha-amino acids is reported. The key step is a BF3.OEt2-mediated reaction of allylsilanes with N-(alkoxycarbonyl)-alpha-methoxyglycinamides 11-15, leading to the corresponding gamma,delta-unsaturated alpha-aminocarboxamides. The genuine S(N)1-character of this process with iminium ion 6 as intermediate is proven in the case of the glycine ester 10. Thus, reaction of enzymatically resolved 10 with pi-nucleophiles leads to racemic products. The most useful iminium precursors are the N-methoxyamides 12-14 providing good yields of coupling products. The most convenient N-protective group is the allyloxycarbonyl group. Deprotection proceeds via a Pd(0)-catalyzed transprotection to the corresponding BOC-protected analogues. Four examples of the enzymatic resolution of alpha-amino carboxamides, by using an L-specific aminopeptidase from Pseudomonas putida, are described in detail. Most notably, secondary N-methoxyamides are good substrates for the enzyme to provide the desired a-amino acids in high optical purity.

  DOI：

  10.1021/jo00051a019
• 作为试剂：
  描述：

  环丁基甲酸 在 2-羟基-5-硝基吡啶 、 草酰氯 、 D-环戊基甘氨酸 、 palladium diacetate 、 silver trifluoroacetate 、 N,N-二甲基甲酰胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 27.0h， 生成 methyl 4-(2-acetylcyclobutyl)benzoate 、 dimethyl 4,4'-(2-acetylcyclobutane-1,3-diyl)dibenzoate
  参考文献：
  名称：

  使用手性瞬态导向基团的 PdII 催化环丁基酮的对映选择性 C(sp3 )-H 芳基化。

  摘要：

  使用手性瞬态导向基团 (TDG) 是开发 Pd II催化的对映选择性 C(sp 3 )−H 活化反应的一种有前途的方法。然而，这种策略具有挑战性，因为 TDG 上的立体中心通常远离 C−H 键，并且共价连接到底物上的 TDG 和游离 TDG 都能够与 Pd II中心配位，这可能导致混合反应复合物。我们报道了使用手性 TDG 的 Pd II催化的脂肪族酮的对映选择性 β-C( sp 3 )−H 芳基化反应。通过连续的 C-H 芳基化反应，由单取代环丁烷有效合成了手性三取代环丁烷，从而证明了该方法从简单起始原料获得结构复杂产物的实用性。缺电子吡啶酮配体的使用对于观察到的对映选择性至关重要。有趣的是，使用不同的银盐可以逆转对映选择性。

  DOI：

  10.1002/anie.202000532

文献信息

• [EN] DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK<br/>[FR] COMPOSÉS DE DIHYDROPYRROLONAPHTYRIDINONE COMME INHIBITEURS DE JAK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010144486A1

  公开（公告）日：2010-12-16

  Disclosed are JAK inhibitors of formula (I) where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.

  揭示了式(I)的JAK抑制剂，其中G1、R1、R2、R3、R4、R5、R6和R7在规范中定义。还披露了含有这些化合物的药物组合物、试剂盒和制造物品，制备这些化合物的方法和材料，以及使用这些化合物治疗涉及免疫系统和炎症的疾病、紊乱和症状的方法，包括类风湿关节炎、血液恶性肿瘤、上皮癌（即癌症）和其他与JAK相关的疾病、紊乱或症状。
• [EN] DIPHENYLAZETIDINONE DERIVATES POSSESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE A ACTIVITE INHIBITRICE DE L'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061452A1

  公开（公告）日：2005-07-07

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  化合物的结构式（其中变量基团如定义所示）及其药学上可接受的盐、溶剂合物、该类盐的溶剂合物和它们的前药，以及它们作为治疗高脂血症的胆固醇吸收抑制剂的用途被描述。还描述了它们的制备方法和含有它们的药物组合物。
• Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
  申请人：Alenfalk Susanne

  公开号：US20080064676A1

  公开（公告）日：2008-03-13

  Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式(I)的化合物（其中变量基团如定义所示），其药学上可接受的盐、此类盐的溶剂化合物、其前药以及其作为治疗高脂血症的胆固醇吸收抑制剂的用途。本文还描述了其制造工艺和含有它们的制药组合物。
• Novel therapeutic compounds
  申请人：Breinlinger Eric C.

  公开号：US20090069288A1

  公开（公告）日：2009-03-12

  Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.

  本文公开了公式（I）的新化合物，其中变量如本文所定义。公式（I）的化合物可用作激酶抑制剂，因此可用于治疗某些疾病和病症，特别是炎症性疾病和疾病以及增生性疾病，如癌症。
• Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
  申请人：AstraZeneca AB

  公开号：US07871998B2

  公开（公告）日：2011-01-18

  Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  本文描述了化学式（I）的化合物：（其中变量基团的定义如下）药学上可接受的盐，其溶剂化物，这些盐的溶剂化物及其前药，并将其用作胆固醇吸收抑制剂，用于治疗高脂血症。还描述了它们的制造过程和含有它们的制药组合物。